GlassScriptPhysician profile
Rachelle Usis
NPI 1871914374
$3,918.25
in general payments reported to CMS, 2019-2025
29 companies · $2,055 in 2025
The $2,055 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $97.70 · 2022: $68.53 · 2023: $380 · 2024: $1,317 · 2025: $2,055.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,752.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $963.34 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $439.48 | 2022-2025 | |
| Glaxosmithkline, LLC. | $437.87 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $421.73 | 2024-2025 | |
| Novo Nordisk INC | $303.25 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $148.57 | 2024-2025 | Repatha, Evenity, Otezla |
| Lilly USA, LLC | $128.12 | 2022-2025 | Mounjaro, Zepbound, Kisunla |
| Merck Sharp & Dohme LLC | $123.86 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Abbott Laboratories | $112.22 | 2021-2023 | Cardiomems |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.64 | 2023-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $102.62 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.15 | 2024-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $59.07 | 2025 | Veozah |
| Eisai INC. | $58.32 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $55.75 | 2024-2025 | Voquezna |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $48.88 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $47.33 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.39 | 2025 | Caplyta |
| Tactile Systems Technology INC | $36.96 | 2025 | Flexitouch Plus, Nimbl |
| Ardelyx, INC. | $31.89 | 2025 | Ibsrela |
| Esperion Therapeutics, INC. | $30.76 | 2021-2025 | Nexletol |
| Amneal Pharmaceuticals LLC | $30.61 | 2024 | Unithroid, Rytary |
| Edwards Lifesciences Corporation | $27.43 | 2025 | Sapien 3 Ultra Resilia |
| Nevro Corp. | $21.18 | 2024 | Senza |
| Kowa Pharmaceuticals America, INC. | $17.60 | 2025 | Zoryve |
| Azurity Pharmaceuticals, INC. | $16.84 | 2023 | Edarbi |
| Teleflex LLC | $16.76 | 2025 | Barrigel |
| Averitas Pharma INC. | $16.32 | 2024 | Qutenza |
| Sanofi Pasteur INC. | $13.31 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachelle Usis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.